https://www.selleckchem.com/pr....oducts/envonalkib.ht
Prostate cancer (PCa) is one of the most frequent tumor types in the male Western population. Early- and late-stage PCa are dependent on androgen signaling, and inhibitors of the androgen receptor (AR) axis represent the standard therapy. Here, we studied in detail the global impact of darolutamide, a newly approved AR antagonist, on the transcriptome and AR-bound cistrome in two PCa cell models. Darolutamide strongly depleted the AR from gene regulatory regions and abolished AR-driven transcriptional signaling. Enhancer activation w
Like
Comment
Share
